Table 1.

Working core outcome measurement set

Core domain	Outcome measurements
	CLE-specific	Dermatologic	Generic
Skin-Specific Disease Activity	CLASI-A	–	–
Investigator Global Assessment of Disease Activity	CLA-IGA*
Skin-Specific Disease Damage	CLASI-D	–	–
Symptoms (pruritus, pain and photosensitivity)	CLEQoL (includes Skindex-29 +3)	DLQI Skindex-29+3 12-Item Pruritus Severity Scale	Itch VAS/NRS Pain VAS/NRS
Health-related Quality of Life	CLEQoL (includes Skindex-29 +3) LEQoL	Skindex-29+3 DLQI	SF-36 EQ-5D
Patient Global Assessment of Disease Activity	–	–	–

*May be considered as a secondary or exploratory endpoint, complementary to CLASI, pending ongoing validation.

CLA-IGA, Cutaneous Lupus Activity Investigator’s Global Assessment; CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity; CLASI-D, Cutaneous Lupus Erythematosus Disease Area and Severity Index-Damage; CLEQoL, Cutaneous Lupus Erythematosus Quality of Life; DLQI, Dermatology Life Quality Index; LEQoL, Lupus Erythematosus Quality of Life Questionnaire; NRS, Numeric Rating Scale; SF-36, Short Form Health Survey; VAS, Visual Analogue Scale.